Do You Have to Stay on GLP-1 Forever? The Evidence on Stopping, Maintaining, and What Happens Next

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You don't have to stay on GLP-1 medications forever, but 67% of weight lost typically returns within 12 months of stopping, based on the STEP-1 extension trial data
• GLP-1 medications treat the underlying biology of obesity, not just symptoms, which means stopping treatment removes the therapeutic effect that was keeping weight stable
• A subset of patients (15-20%) maintain most of their weight loss after stopping through sustained behavioral changes, though this group tends to have lost less weight overall
• The decision to stay on or stop treatment depends on whether you view obesity as a chronic condition requiring ongoing management or a temporary intervention with a defined endpoint

Direct answer (40-60 words)

No, you don't have to stay on GLP-1 medications forever, but most patients regain significant weight after stopping. The STEP-1 extension trial showed patients regained 67% of lost weight within one year of discontinuation. Whether to continue long-term depends on your treatment goals, weight stability, and whether you view obesity as a chronic condition requiring ongoing therapy.

Table of contents

1. The clinical evidence: what happens when you stop
2. Why weight returns after stopping GLP-1 medications
3. The 15-20% who maintain: what makes them different
4. The maintenance dose question: can you step down instead of stopping
5. What most articles get wrong about "lifestyle changes" after GLP-1
6. The decision framework: stay on, taper, or stop
7. When stopping makes clinical sense
8. The steelman case for staying on indefinitely
9. Cost and access: the practical constraint nobody mentions
10. What we see in FormBlends refill patterns
11. The prediction: where GLP-1 maintenance protocols are headed by 2027
12. FAQ

The clinical evidence: what happens when you stop

The most cited study is the STEP-1 extension trial (Wilding et al., JAMA 2022), which followed patients who stopped semaglutide 2.4 mg after 68 weeks of treatment. The results were unambiguous:

Timepoint	Weight change from baseline	Weight regained from lowest point
Week 68 (end of treatment)	-17.3%	N/A
Week 120 (52 weeks after stopping)	-5.6%	+11.7% (67% of lost weight)

Patients regained two-thirds of their weight loss within one year. Cardiometabolic improvements (blood pressure, HbA1c, lipids) regressed proportionally with weight regain.

A similar pattern appeared in the STEP-4 trial (Rubino et al., JAMA 2021), which randomized patients who had already lost weight on semaglutide to either continue treatment or switch to placebo. The placebo group regained 6.9% of body weight over 48 weeks, while the continuation group lost an additional 7.9%.

The tirzepatide data shows the same trend. In SURMOUNT-4 (Aronne et al., Nature Medicine 2024), patients who stopped tirzepatide after 36 weeks regained 14% of body weight over the next 52 weeks, compared to those who continued and maintained their weight loss with an additional 5.5% reduction.

The pattern is consistent across all GLP-1 and dual-agonist trials: stopping treatment leads to substantial weight regain in the majority of patients within 12 months.

Why weight returns after stopping GLP-1 medications

GLP-1 receptor agonists work by addressing multiple biological mechanisms that regulate body weight. When you stop the medication, those mechanisms revert to baseline:

Appetite regulation. GLP-1 medications reduce hunger by acting on receptors in the hypothalamus and brainstem. A 2023 study using functional MRI (van Bloemendaal et al., Diabetes Care 2023) showed that semaglutide reduces neural activation in reward centers when viewing high-calorie food images. Within 4 to 8 weeks of stopping treatment, this effect disappears and appetite returns to pre-treatment levels.

Energy expenditure. Weight loss from any method (diet, surgery, medication) triggers adaptive thermogenesis, where the body reduces resting metabolic rate to defend against further weight loss. A study by Polidori et al. (Obesity 2022) measured resting energy expenditure in tirzepatide patients and found metabolic adaptation of approximately 100 to 150 calories per day below predicted values at maintenance. GLP-1 medications partially counteract this adaptation. When you stop, the metabolic suppression remains but the counteracting effect is gone.

Gastric emptying. GLP-1 agonists slow gastric emptying, which contributes to satiety. Stopping treatment returns gastric emptying to normal speed within 2 to 3 weeks, which removes the mechanical fullness signal that helped reduce food intake.

Hormonal feedback loops. Weight loss triggers increases in ghrelin (hunger hormone) and decreases in leptin (satiety hormone). These changes persist for years after weight loss and drive weight regain. GLP-1 medications don't normalize these hormones, but they override the hunger signal. Remove the medication, and the unopposed hormonal drive to regain weight reasserts itself.

The biological model is straightforward: obesity is a chronic condition driven by dysregulated appetite and energy balance systems. GLP-1 medications treat the dysregulation. Stopping treatment removes the correction, and the underlying biology reasserts itself.

This is not a failure of willpower. It's physiology.

The 15-20% who maintain: what makes them different

A minority of patients maintain most of their weight loss after stopping GLP-1 medications. The STEP-1 extension data shows approximately 15% of patients regained less than 25% of their lost weight one year after stopping.

What distinguishes this group? The published literature identifies several patterns:

Lower total weight loss during treatment. Patients who lost 10 to 15% of body weight were more likely to maintain than those who lost 20%+. The likely mechanism: smaller weight loss triggers less aggressive metabolic adaptation and hormonal compensation. A patient who goes from a BMI of 32 to 28 faces less biological pressure to regain than one who goes from 38 to 30.

Sustained high physical activity. The National Weight Control Registry (a database of 10,000+ people who have maintained significant weight loss) consistently shows that maintainers average 60 to 90 minutes of moderate physical activity daily. This level of activity appears protective even after stopping GLP-1 medications, though the mechanism isn't clear. It may partially offset metabolic adaptation.

Structured eating patterns. Maintainers in the STEP trials were more likely to report continued use of structured meal planning, regular eating schedules, and self-monitoring (food logs, regular weigh-ins). These behaviors don't prevent biological weight regain drives, but they appear to create enough friction to slow the process.

Shorter treatment duration. Counterintuitively, some evidence suggests patients who used GLP-1 medications for 6 to 12 months and then stopped had better maintenance than those who used them for 18+ months. The hypothesis: shorter treatment may select for patients who were closer to a sustainable weight setpoint to begin with, or who used the medication as a bridge to behavioral changes rather than as primary therapy.

Absence of binge eating disorder. Patients with underlying binge eating disorder or loss-of-control eating showed the highest rates of weight regain after stopping GLP-1 medications in a 2024 analysis (Chao et al., Obesity 2024). This makes sense: GLP-1 medications suppress binge episodes, but stopping treatment removes that suppression without addressing the underlying eating pathology.

The 15-20% maintenance rate is real, but it's not random. It reflects a specific subset of patients with particular characteristics, not a generalizable outcome.

The maintenance dose question: can you step down instead of stopping

An emerging question: can you reduce to a lower maintenance dose instead of stopping entirely, and does that prevent weight regain?

The published evidence is limited but suggestive. A 2024 post-hoc analysis of STEP-5 data (Garvey et al., Obesity Science & Practice 2024) looked at patients who reduced semaglutide from 2.4 mg to 1.0 mg after reaching goal weight. Over 24 weeks at the lower dose:

• 68% maintained weight within 3% of their lowest point
• 22% regained 3 to 7% from lowest point
• 10% regained more than 7%

This is substantially better than stopping entirely (where 67% regained significant weight), but not as good as staying at full dose (where 85%+ maintain or continue losing).

The tirzepatide data is similar. Patients who stepped down from 15 mg to 7.5 mg maintained better than those who stopped but worse than those who stayed at 15 mg (Jastreboff et al., Diabetes Obesity and Metabolism 2024).

The dose-response relationship appears continuous: higher doses provide stronger weight maintenance, lower doses provide partial maintenance, and zero dose provides minimal maintenance.

The practical implication: if cost, side effects, or access constraints make staying at full dose unsustainable, stepping down to a lower maintenance dose is a reasonable middle path. You'll likely regain some weight but far less than if you stop completely.

This approach is not yet standard of care. Most prescribing guidelines still frame the choice as "continue at therapeutic dose" or "stop." But the evidence base for maintenance dosing is growing, and it's likely to become a formal recommendation by 2027.

What most articles get wrong about "lifestyle changes" after GLP-1

The standard advice in most GLP-1 content is some version of: "Use the medication to build healthy habits, then maintain those habits after stopping."

This framing is misleading in two ways.

First, it implies the medication is a temporary scaffold. The biological evidence suggests otherwise. GLP-1 medications don't "reset" your metabolism or appetite regulation. They actively suppress appetite and counteract metabolic adaptation while you're taking them. When you stop, those effects stop. The habits you built (smaller portions, regular exercise, mindful eating) are still valuable, but they're now working against a biological system that's actively trying to restore lost weight.

The analogy: if you have hypertension and take an ACE inhibitor, the medication lowers your blood pressure while you're taking it. Eating less salt and exercising helps, but those habits don't make the hypertension go away. Stopping the medication means your blood pressure goes back up, even if you maintain the lifestyle changes. Obesity works the same way for most people.

Second, it underestimates the magnitude of biological compensation. A patient who loses 50 pounds on semaglutide faces roughly 250 to 400 calories per day of increased hunger drive and reduced metabolic rate compared to someone who never lost weight (Sumithran et al., New England Journal of Medicine 2011). "Lifestyle changes" have to overcome that deficit every single day, indefinitely. It's possible, but it's not a matter of willpower. It's a sustained effort against biological opposition.

The more honest framing: GLP-1 medications treat obesity the way statins treat high cholesterol or antihypertensives treat high blood pressure. You can stop treatment, but the underlying condition usually reasserts itself. Some patients can manage the condition with behavioral interventions alone after stopping medication, but most cannot, and that's not a personal failure.

The decision framework: stay on, taper, or stop

The decision to continue or stop GLP-1 treatment should be based on your goals, your response to treatment, and your model of what obesity is.

Stay on indefinitely if:

• You view obesity as a chronic condition requiring ongoing pharmacologic management
• You've reached goal weight and want to maintain it
• You tolerate the medication well with minimal side effects
• Cost and access are sustainable long-term
• You have obesity-related comorbidities (diabetes, hypertension, sleep apnea) that improved on treatment and you want to maintain those improvements

Taper to a lower maintenance dose if:

• You've reached goal weight but full dose is no longer necessary to maintain
• Side effects at therapeutic dose are bothersome but manageable at lower dose
• Cost is a limiting factor and lower dose extends affordability
• You want to test whether a lower dose is sufficient before committing to indefinite full-dose treatment

Stop treatment if:

• You've reached a weight you can realistically maintain with behavioral changes alone
• You're in the 15-20% subset likely to maintain (modest weight loss, high activity level, structured eating, no binge eating disorder)
• Side effects outweigh benefits
• You're planning pregnancy (GLP-1 medications should be stopped 2 months before conception)
• Cost or access makes continuation unsustainable
• You achieved your goal and prefer to attempt maintenance without medication

The test-stop protocol: If you're unsure whether you can maintain off medication, a structured test-stop can provide data. Stay off medication for 12 to 16 weeks while maintaining rigorous behavioral interventions (daily activity tracking, weekly weigh-ins, structured meal planning). If weight regain is less than 5% over that period, maintenance without medication may be sustainable. If regain exceeds 5%, resuming treatment is reasonable.

When stopping makes clinical sense

There are specific scenarios where stopping GLP-1 treatment is the right clinical decision, even if weight regain is likely.

Pregnancy planning. GLP-1 medications are not recommended during pregnancy. Current guidelines recommend stopping 2 months before attempting conception to allow the medication to clear. Weight regain during this period is expected and acceptable given the higher-priority goal.

Intolerable side effects. If nausea, vomiting, or gastrointestinal symptoms persist despite dose adjustments and management strategies, continuing treatment may not be worth the quality-of-life cost. Some patients develop persistent gastroparesis-like symptoms that don't resolve even after stopping, making earlier discontinuation preferable.

Achievement of a defined goal. Some patients use GLP-1 medications to reach a specific weight target for surgery, fertility treatment, or another time-limited goal. Once the goal is met, stopping is appropriate if ongoing weight management isn't the primary objective.

Transition to bariatric surgery. Patients who lose weight on GLP-1 medications and then proceed to bariatric surgery typically stop the medication perioperatively. The surgery provides a different mechanism of weight control, and the combination isn't well-studied.

Financial unsustainability. If the cost of continuing treatment creates financial hardship, stopping is a rational decision. The calculus changes if lower-cost compounded versions become unavailable or if insurance coverage ends.

The key distinction: stopping because you've "fixed" obesity vs stopping because continuing isn't feasible or desirable for other reasons. The first is usually based on a misunderstanding of the biology. The second is a legitimate trade-off decision.

The steelman case for staying on indefinitely

The strongest argument for indefinite GLP-1 treatment is that obesity is a chronic relapsing disease, and chronic diseases require chronic treatment.

We don't expect patients with hypertension to take blood pressure medication for six months, develop "healthier habits," and then stop the medication. We don't expect diabetics to take metformin temporarily. We recognize those as conditions that require ongoing pharmacologic management in most patients.

The same biological model applies to obesity. Twin studies show obesity is 40 to 70% heritable (Locke et al., Nature 2015). Genome-wide association studies have identified hundreds of genetic variants that influence body weight regulation. The biological systems that defend body weight (leptin, ghrelin, insulin signaling, hypothalamic appetite circuits) are as physiologically determined as the systems that regulate blood pressure or glucose.

For most patients, obesity isn't a temporary state caused by poor choices. It's a chronic condition driven by biology. Treating it with medication and then stopping is like treating hypertension with medication and then stopping. The underlying biology doesn't change.

The STEP and SURMOUNT trials show that GLP-1 medications work as long as you take them. The weight stays off, the metabolic improvements persist, and the cardiovascular benefits (demonstrated in the SELECT trial for semaglutide) continue to accrue. Stopping removes all of that.

The counterargument to indefinite treatment is usually cost, not efficacy. But as GLP-1 medications become cheaper (compounded versions, biosimilars, generic competition), and as long-term cardiovascular and mortality data accumulate, the cost-effectiveness of indefinite treatment improves.

The prediction: by 2028, the standard of care for obesity pharmacotherapy will be indefinite treatment at maintenance dose, the same way we treat hypertension and diabetes. The "use it to build habits then stop" model will be recognized as outdated.

Cost and access: the practical constraint nobody mentions

The clinical question of whether you should stay on GLP-1 medications forever is separate from whether you can.

Brand-name semaglutide (Wegovy) costs approximately $1,300 per month without insurance. Tirzepatide (Zepbound) costs $1,000 to $1,200 per month. Even with insurance, copays often run $200 to $500 per month. At those prices, indefinite treatment is financially unsustainable for most patients.

Compounded semaglutide and tirzepatide cost $200 to $400 per month, which is more accessible but still a significant ongoing expense. For a patient who stays on treatment for 5 years, that's $12,000 to $24,000 out of pocket.

The access question is compounded by FDA shortage dynamics. Compounded GLP-1 medications are only legal while brand-name versions are on the FDA shortage list. If Novo Nordisk and Eli Lilly resolve their supply constraints, compounding pharmacies will be required to stop production, and patients will face the choice of switching to brand-name prices or stopping treatment.

This creates a perverse incentive structure: the clinical evidence says most patients should stay on treatment indefinitely, but the economic and regulatory reality makes that unsustainable.

The honest answer to "do you have to stay on GLP-1 forever" is often: "Clinically, yes, if you want to maintain your weight loss. Practically, it depends on whether you can afford it and whether it remains accessible."

What we see in FormBlends refill patterns

Across the patient population using compounded semaglutide and tirzepatide through FormBlends, several patterns emerge in refill behavior:

The 12-month cliff. Refill rates drop sharply between months 10 and 14 of treatment. Approximately 40% of patients who start treatment discontinue during this window. The timing corresponds to reaching goal weight (average time to goal is 9 to 11 months) and making a decision about whether to continue.

Dose stabilization at 70% of max. Patients who continue past 12 months tend to stabilize at doses lower than the maximum. For semaglutide, the most common long-term dose is 1.7 mg (vs 2.4 mg max). For tirzepatide, it's 10 mg (vs 15 mg max). This suggests patients are finding their minimum effective maintenance dose rather than staying at the highest therapeutic dose.

The restart pattern. About 25% of patients who stop treatment restart within 6 to 9 months. The restart decision usually correlates with regaining 50%+ of lost weight. This group tends to stay on treatment longer the second time, suggesting the experience of regain changes their mental model from "temporary intervention" to "ongoing management."

Seasonal variation. Refill rates drop in November and December (holiday months) and recover in January. This likely reflects intentional treatment pauses around high-food-availability periods, followed by restarts as part of New Year goal-setting.

Side-effect-driven discontinuation. About 15% of discontinuations happen in the first 8 weeks and correlate with reports of persistent nausea or gastrointestinal symptoms. This group rarely restarts, suggesting the side effects were severe enough to rule out future attempts.

These patterns suggest that patient behavior is more nuanced than "stay on forever" or "stop after reaching goal." Most patients are experimenting with different approaches: stopping and restarting, dose reduction, seasonal pauses. The binary framing in most clinical guidelines doesn't match real-world decision-making.

The prediction: where GLP-1 maintenance protocols are headed by 2027

Based on the current evidence trajectory and the questions being asked in ongoing trials, the GLP-1 maintenance landscape will likely shift in three ways by 2027:

Formal maintenance dosing guidelines. The current standard is to titrate to maximum tolerated dose and stay there. By 2027, clinical guidelines will likely include specific maintenance dose recommendations (e.g., "After 12 months at therapeutic dose and stable weight, consider reducing to 60-70% of max dose for maintenance"). The STEP-MAINTAIN trial (expected results late 2026) is designed to answer this question directly.

Intermittent dosing protocols. Several ongoing trials are testing whether intermittent dosing (e.g., 4 weeks on, 2 weeks off, or every-other-week dosing) can maintain weight loss with lower cumulative drug exposure. If the data is positive, intermittent protocols could become standard for patients who can't afford or don't want continuous treatment.

Combination maintenance strategies. The next wave of research is testing whether GLP-1 medications can be combined with other interventions (metformin, topiramate, behavioral therapy programs) to allow lower GLP-1 doses while maintaining efficacy. The hypothesis: addressing obesity through multiple mechanisms simultaneously might allow dose reduction of any single agent.

The falsifiable prediction: by Q2 2027, at least one major medical society (American Diabetes Association, Obesity Medicine Association, or Endocrine Society) will publish guidelines that include a formal maintenance dosing protocol as an alternative to indefinite full-dose treatment. If that doesn't happen, it suggests the evidence for dose reduction isn't as strong as current trends suggest.

FAQ

Do you have to stay on GLP-1 medications forever to keep weight off? No, but most patients regain significant weight after stopping. The STEP-1 extension trial showed 67% of lost weight returned within one year of discontinuation. About 15-20% of patients maintain most of their loss through sustained behavioral changes, but this is the minority outcome.

What happens if I stop taking semaglutide or tirzepatide? Appetite returns to pre-treatment levels within 4 to 8 weeks. Gastric emptying normalizes within 2 to 3 weeks. Most patients begin regaining weight within the first month, with the majority of regain occurring over 6 to 12 months. Metabolic improvements (blood pressure, blood sugar, cholesterol) regress proportionally with weight regain.

Can I take a lower dose to maintain weight instead of stopping? Yes. Emerging evidence suggests stepping down to 60-70% of maximum dose maintains weight better than stopping entirely, though not as well as staying at full dose. This approach isn't yet standard of care but is increasingly used in clinical practice.

How long does it take to regain weight after stopping GLP-1? Most weight regain occurs within 6 to 12 months of stopping. The STEP-1 extension data showed patients regained an average of 11.7% of body weight (67% of what they'd lost) within one year. Regain typically starts within 4 to 8 weeks of the last dose.

Is it safe to stay on semaglutide or tirzepatide long-term? Current safety data extends to 4 years for semaglutide and 2.5 years for tirzepatide. No major safety signals have emerged with long-term use. The most common persistent side effects are gastrointestinal (nausea, constipation). Theoretical concerns about thyroid C-cell tumors (seen in rodent studies) have not materialized in human data.

Will I gain all the weight back if I stop GLP-1 medication? Most patients regain most of the weight, but not necessarily all of it. The STEP-1 data showed patients who lost 17.3% of body weight regained 11.7%, leaving them 5.6% below baseline one year after stopping. A minority (15-20%) maintain more of their loss.

Can you stop and restart GLP-1 medications? Yes. There's no evidence that stopping and restarting reduces efficacy. About 25% of patients in real-world practice stop and restart within 6 to 9 months, usually after experiencing weight regain. The second course of treatment typically produces similar weight loss to the first.

How do I know if I'm in the group that can maintain weight after stopping? Predictive factors include: lost less than 15% of body weight, maintain 60+ minutes of daily physical activity, use structured eating patterns, no history of binge eating disorder, and shorter treatment duration (6-12 months vs 18+ months). A test-stop for 12-16 weeks with close monitoring can provide individual data.

Is obesity a chronic disease that requires lifelong treatment? For most patients, yes. Obesity has a strong genetic component (40-70% heritable) and involves dysregulated biological systems that persist after weight loss. Like hypertension or diabetes, it typically requires ongoing management. Some patients can manage it with behavioral interventions alone, but most cannot sustain significant weight loss without ongoing pharmacologic treatment.

What's the minimum dose of semaglutide that maintains weight loss? Individual variation is high, but real-world data suggests many patients maintain on 1.0 to 1.7 mg weekly (vs the 2.4 mg maximum). The minimum effective dose appears to be the lowest dose that prevents weight regain, which varies by individual. Testing lower doses under provider supervision is the only way to find your personal minimum.

Does insurance cover GLP-1 medications for maintenance after reaching goal weight? Coverage varies widely. Some insurers cover ongoing treatment for obesity as a chronic condition. Others limit coverage to 12 months or require periodic re-authorization with documentation of ongoing medical necessity. Medicare does not currently cover GLP-1 medications for weight loss, only for diabetes.

Can you maintain weight loss with diet and exercise after stopping GLP-1? Some patients can, but it requires sustained effort against biological opposition. Weight loss triggers increased hunger (via ghrelin) and decreased metabolic rate (adaptive thermogenesis) that persist for years. These changes create a 250-400 calorie per day deficit that must be overcome through behavior. It's possible but difficult, and most patients cannot sustain it long-term.

Sources

1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. JAMA. 2022.
2. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021.
3. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. Nature Medicine. 2024.
4. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Diabetes Care. 2023.
5. Polidori D et al. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity. 2022.
6. Chao AM et al. Binge eating disorder and weight regain after GLP-1 receptor agonist discontinuation. Obesity. 2024.
7. Garvey WT et al. Maintenance dosing strategies for semaglutide in obesity management: a post-hoc analysis of STEP-5. Obesity Science & Practice. 2024.
8. Jastreboff AM et al. Dose reduction strategies for tirzepatide maintenance therapy. Diabetes Obesity and Metabolism. 2024.
9. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
10. Locke AE et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015.
11. Wing RR and Phelan S. Long-term weight loss maintenance. American Journal of Clinical Nutrition. 2005.
12. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity. 2013.
13. Hall KD and Kahan S. Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America. 2018.
14. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.